Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Zymeworks (ZYME) News Today

Zymeworks logo
$28.22 -0.22 (-0.77%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$27.44 -0.78 (-2.75%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is Zymeworks Down Today?

Zymeworks Inc. (NASDAQ: ZYME) shares are increasing as investors react to a potentially significant licensing and collaboration agreement with Roche for ZW209, an experimental trispecific T-cell engager targeting DLL3 in small-cell lung cancer and other solid tumors.

  • Positive Sentiment: Meaningful upfront and milestone potential: Zymeworks will receive $55 million upfront, another $40 million when the Phase 1b trial begins, and up to $718 million in additional development, commercial and sales milestones. The deal also includes tiered royalties ranging from high-single-digit percentages to the mid-teens on potential global sales. Zymeworks Roche ZW209 collaboration announcement
  • Positive Sentiment: Risk-sharing with a major pharmaceutical partner: Roche will fund the Phase 1a trial and assume responsibility for subsequent global development and commercialization. This gives ZW209 access to Roche’s clinical, manufacturing and commercial resources while reducing Zymeworks’ future development burden.
  • Positive Sentiment: Clinical development is advancing: ZW209 has received U.S. FDA investigational new drug clearance, allowing a Phase 1 study to evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity. The program is designed to engage DLL3-positive tumor cells and activate T cells through both CD3 and CD28.
  • Neutral Sentiment: Early-stage asset: ZW209 remains an investigational therapy, so the milestone payments, royalties and commercial opportunity depend on successful clinical results, regulatory approvals and eventual market adoption. Management plans to discuss the agreement with investors on October 27, 2026.
  • Negative Sentiment: Limited control over the program: Roche receives exclusive worldwide development and commercialization rights. The transaction also remains subject to customary closing conditions and expiration or termination of the Hart-Scott-Rodino antitrust waiting period.

The agreement is especially important because Zymeworks has faced substantial financial pressure, including sharply lower recent revenue and continuing operating losses. The upfront cash and Roche partnership could improve financial flexibility, while the potential milestones and royalties add value beyond the company’s existing licensed-asset portfolio.

Posted 1+ days agoAI Generated. May Contain Errors.

Zymeworks Latest News

Zymeworks stock surges on $813M Roche licensing deal
Zymeworks Inc. Updates Earnings Guidance for the Year 2026
Zymeworks Issues Updated 2026 Financial Guidance
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks (ZYME), What Is Behind The Renewed Attention?
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Wells Fargo Remains a Buy on Zymeworks (ZYME)

Zymeworks Media Mentions By Week

Zymeworks Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ZYME
News Sentiment
▼
0.25

0.46
▲
Average
Healthcare
News Sentiment

Zymeworks News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ZYME Articles
This Week
▼
12

5
▲
ZYME Articles
Average Week

Zymeworks Trends on MarketBeat

This week vs. last week
New Followers
1
Searches
2
+100%
Page Views
2,491
+1%
Get Zymeworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Zymeworks dated 10/24/2026.
From Our Partners